According to Pangu, multiple e-commerce platforms have already launched prescription services for Li Le's glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide (brand name: Moubingda). The indications for tirzepatide include diabetes and weight loss, and the prices on the platforms vary.
Li Le China clarified that tirzepatide is a self-pay medication, and patients should refer to the pricing set by major pharmaceutical institutions.
On the issue of supply, Li Le China stated that the company is producing and shipping large quantities of tirzepatide every day, a unprecedented level of production to meet patient demand. The factories are operating 24/7, and new manufacturing facilities are being built overnight to increase supply.